Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Aim(s): To evaluate the dynamics of CgA changes and its prognostic significance during treatment with radiolabelled somatostatin analogs (PRRT) in patients with G1/G2 NET.
Materials and methods: 91 patients, mean age 56, treated with PRRT were included. Radiolabelled with 90Y or 177Lu DOTATATE was delivered in 4 to 5 cycles at 6-12 weeks intervals. After completion of PRRT, patients were randomized to biotherapy with SSA or observation. Chromogranin A was evaluated before each treatment cycle, 6-12 weeks after treatment, and then during at 6-12 months. An increase or decrease of at least 25% was considered significant.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.